WALD WALDENCAST ACQUISITION CORP

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates

First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, provided additional details for its upcoming earnings release and conference call dates. The Company currently expects to issue Second Quarter Fiscal 2025 Results and Q3 2025 Financial Results on November 24, 2025. The Company does not plan to host a conference call with respect to these results given its ongoing strategic review.

About Waldencast plc

Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: .

Contacts

Investors

ICR

Allison Malkin

Media

ICR

Brittany Fraser/Alecia Pulman



EN
12/11/2025

Underlying

WALDWALDENCAST ACQUISITION CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WALDENCAST ACQUISITION CORP

 PRESS RELEASE
Free
WALD WALDENCAST ACQU...

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Inject...

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the recent American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place November 13–16, 2025, in Chicago, Il...

11h / 36m 1 EN
 PRESS RELEASE
Free
WALD WALDENCAST ACQU...

Waldencast plc strengthens balance sheet position with the announcemen...

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million. Since 2002, Rohto has licensed the “Obagi” mark for use in the Japanese market to commercialize Rohto’s products. During that time, Rohto has devel...

November 14, 2025 1 EN
 PRESS RELEASE
Free
WALD WALDENCAST ACQU...

Waldencast plc Provides Information Regarding Upcoming Earnings Releas...

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, provided additional details for its upcoming earnings release and conference call dates. The Company currently expects to issue Second Quarter Fiscal 2025 Results and Q3 2025 Financial Results on November 24, 2025. The Company does not plan to host a conference call wi...

November 12, 2025 1 EN
 PRESS RELEASE
Free
WALD WALDENCAST ACQU...

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), the fastest growing professional skincare brand in the U.S. in 2024*, proudly unveils its latest innovation rooted in clinical skin science: Nu-Cil® BioStim™ Scalp Serum. Designed to promote a healthier scalp, the foundation of fuller, stronger hair, this advanced leave-in serum is clinically proven to reduce dry, fallen hair by 74% in just three months, helping deliv...

October 8, 2025 1 EN
 PRESS RELEASE
Free
WALD WALDENCAST ACQU...

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable ...

Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, today announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product ...

September 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch